Quantcast

Latest Eisai Stories

2014-02-27 08:30:00

Patient Recruitment Now Underway at Treatment Centers Across the United States WOODCLIFF LAKE, N.J., Feb. 27, 2014 /PRNewswire/ -- Eisai Inc. today announced the start of a large, randomized Phase 3 trial to compare the efficacy, safety and tolerability of eribulin mesylate to standard weekly paclitaxel as a first- or second- line treatment for HER2-negative locally recurrent or metastatic breast cancer (MBC). Recruitment is currently active for this multicenter study, conducted in...

2014-02-21 08:25:37

Preclinical Study Results Published in the Journal Molecular Cancer Therapeutics Show Sustained Efficacy of EZH2 Inhibitor in Animal Models CAMBRIDGE, Mass., Feb. 21, 2014 /PRNewswire/ -- Epizyme, Inc., (NASDAQ: EPZM) a clinical stage biopharmaceutical company creating innovative personalized therapeutics for patients with genetically defined cancers, announced today the publication of data from preclinical studies of the company's clinical candidate EPZ-6438 (E7438), a potent and selective...

2014-02-12 08:28:44

-- Eisai's Filing for Approval of BELVIQ as a Treatment for Chronic Weight Management Triggers $500,000 Milestone Payment to Arena -- SAN DIEGO, Feb. 12, 2014 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today that Eisai Laboratorios Ltda., a subsidiary of Eisai Inc., has filed for marketing authorization of BELVIQ® as a treatment for chronic weight management with the Brazilian Health Surveillance Agency (Anvisa). In connection with the filing, Arena will receive a...

2014-02-10 08:26:18

Number of Insured Commercial Lives in the U.S. with Coverage for BELVIQ® Now Exceeds 50 Percent WOODCLIFF LAKE, N.J., Feb. 10, 2014 /PRNewswire/ -- Eisai Inc. reported today that it has secured improved patient access of BELVIQ® (lorcaserin HCl) with two leading healthcare benefit companies: CVS Caremark and Aetna. CVS Caremark customers (employers and health plans) have broadened the coverage of Eisai's BELVIQ, according to Fingertip Formulary, an integrated database of formulary...

2014-02-03 04:20:02

Tokyo, Feb 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. announced today that it will launch the vascular embolization device DC Bead(R) (specially controlled medical device) in Japan on February 4.DC Bead contains hydrophilic microspheres made from cross-linked polyvinyl alcohol polymer. Developed by Biocompatibles UK Limited (Biocompatibles), a BTG International group company, as an intravascular embolization device, it is injected via catheter into targeted blood...

2014-02-03 00:21:05

WOODCLIFF LAKE, N.J., Feb. 2, 2014 /PRNewswire/ -- Eisai Inc. announced today that the Phase 3 SELECT trial (Study 303) of investigational agent lenvatinib met its primary endpoint. Compared to placebo, lenvatinib showed a highly statistically significant improvement in progression free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RR-DTC). The preliminary safety analyses showed that the five most common adverse reactions were hypertension,...

2014-01-02 08:23:03

FYCOMPA is the First and Only FDA-Approved Non-Competitive AMPA Glutamate Receptor Antagonist WOODCLIFF LAKE, N.J., Jan. 2, 2014 /PRNewswire/ -- Eisai Inc. announced today that FYCOMPA(TM) (perampanel) CIII will be available to eligible patients by prescription in the U.S. beginning January 6, 2014. FYCOMPA is an adjunctive therapy for the treatment of partial-onset seizures with or without secondarily generalized seizures in patients with epilepsy age 12 years and older. FYCOMPA is...

2013-12-05 23:04:28

Reportbuyer.com just published a new market research report: Drug Delivery Partnering Terms and Agreements. London (PRWEB) December 05, 2013 The Drug Delivery Partnering Terms and Agreements report provides comprehensive understanding and unprecedented access to the drug delivery partnering deals and agreements entered into by the worlds leading healthcare companies. The report provides a detailed understanding and analysis of how and why companies enter drug delivery partnering deals....


Word of the Day
barratry
  • The offense of persistently instigating lawsuits, typically groundless ones.
  • An unlawful breach of duty on the part of a ship's master or crew resulting in injury to the ship's owner.
  • Sale or purchase of positions in church or state.
This word ultimately comes from the Old French word 'barater,' to cheat.
Related